Such patients may be less responsive to positive inotropic agents, whereas the beneficial effects of nesiritide, which are not dependent on the β-adrenergic receptor signal-transduction pathway ...

Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the ...

AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE ® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously ...

GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

4,8-9 Patients with EGFRm NSCLC are particularly sensitive to treatment with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) which blocks the cell-signaling pathways that drive the growth of tumor cells.

Li, T. , Zeng, X. and Wu, Y. (2024) Pneumocephalus Following Combined Spinal-Epidural Anesthesia: A Case Report Analysis.

Belzutifan is a first-in-class oral HIF-2a inhibitor that impedes heterodimerization with HIF-1b and downstream oncogenic pathways. To be eligible for ... hypoxia, dizziness, dyspnea, fatigue, nausea, ...

Belzutifan is a first-in-class oral HIF-2a inhibitor that impedes heterodimerization with HIF-1b and downstream oncogenic pathways. In December 2023 ... hypoxia, dizziness, dyspnea, fatigue, nausea, ...

However, the exact pathway and mechanism of gastrointestinal tumor metastasis ... However, in our case, the patient initially presented with dyspnea and symptoms resembling a respiratory infection, ...

They range from paraneoplastic syndrome, dyspnea, and ST-segment elevation on an electrocardiogram ... Consequently, targeted therapy directed at microenvironmental signaling pathways may offer a ...